PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dabigatran etexilate - VTE prevention post hip/knee replacement
PAD Profile : Dabigatran etexilate - VTE prevention post hip/knee replacement
Keywords :
NOAC, anticoagulant cards, anticoagulant alert cards
Brand Names Include :
Pradaxa
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Atrial fibrillation
- Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
- VTE treatment and prevention (children)
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
01 June 2016
Surrey Medicines Commissioners Group
Surrey Medicines Commissioning Group recommend that patients prescribed all types of anticoagulants (warfarin and NOACs) should be given an anticoagulant alert card to carry with them. For patients taking NOACs, the card should be annotated on the reverse in the “Therapeutic range (INR)” box with the words “not applicable” or “not required for this drug”.
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
20 May 2009
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The committee confirmed that dabigatran should be considered a hospital only RED drug for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Associated BNF Codes
02. Cardiovascular System
02.08.02. Oral anticoagulants